Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients

NCT03627026 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT03627026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03627026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients
Lead sponsor
Institut Claudius Regaud
Phase
Not applicable
Overall status
Completed
Start date
June 11, 2019
Completion date
June 3, 2024
Enrollment
78 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma